Osteogenesis Imperfecta Clinical Trial
Official title:
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV
The primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.
Participants will be randomized 1:1 to receive either setrusumab or IV-BP. Following randomization, participants will receive setrusumab or IV-BP for up to 24 months during the Active-controlled Period. At the end of the Active-controlled Period all participants will enter the Extension Period and participants assigned to IV-BP will transition to setrusumab. During the Extension Period, all participants will receive setrusumab for a minimum of 12 months or until setrusumab becomes commercially available in their respective country or the study is discontinued. The use of any bisphosphonate is prohibited throughout the Extension Period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
| Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
| Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
| Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
| Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
| Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
| Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
| Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
| Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
| Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
| Not yet recruiting |
NCT05612139 -
Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients
|
||
| Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
| Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
| Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
| Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
| Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
| Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
| Suspended |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
| Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 |